Spero Therapeutics

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Spero Therapeutics reports progress in drug candidates and financial stability

Spero Therapeutics showcased progress in key drug candidates and financial stability.
Efficient management of expenses and strong cash position support future operations.
Challenges include successful Phase III trials and proof of concept for key treatments.
Opportunities lie in market potential for drug candidates and positive financial outlook.

Spero Therapeutics advances clinical programs and strengthens financial position

Spero Therapeutics demonstrated strong clinical and financial performance in Q1 2023, with a robust pipeline and efficient cost management.
While facing timeline challenges and the need for regulatory milestones, the company's strengths in infectious disease treatments and strategic partnerships present growth opportunities.
By addressing challenges, leveraging strengths, and capitalizing on opportunities, Spero is poised for continued success and potential market leadership in the pharmaceutical sector.

Spero Therapeutics reports Q2 progress with strategic leadership changes

Spero Therapeutics reported Q2 revenues of $2.7 million with a net loss of $11.9 million, holding $77.7 million in cash.
Progress in late-stage clinical programs and management changes signal strategic advancements and leadership continuity.
Challenges include managing R&D investments, competitive market dynamics, and clear execution of growth strategies.
Opportunities lie in revenue growth from milestones, pipeline expansion, differentiation strategies, and strategic partnerships.

Spero Therapeutics reports strong Q3 performance amidst strategic shifts

Spero Therapeutics showcased solid revenue generation and cash reserves in Q3 2023, underpinned by strategic partnerships and pipeline advancements.
While facing challenges such as increased expenses and impairment costs, the company's leadership changes and innovative programs position it for long-term success.
Opportunities lie in upcoming clinical data releases, expansion of product pipelines, and substantial revenue potential from key partnerships, signaling a promising outlook for Spero.

Spero Therapeutics excels in antibiotic development with strong financial backing

Spero Therapeutics demonstrated strong performance in advancing key programs and securing financial support, positioning the company for future growth.
While facing challenges in enrollment and funding, the opportunities in addressing critical infections present a promising outlook for Spero Therapeutics.

Spero Therapeutics reports Q2 revenue growth amidst leadership transition

Spero Therapeutics showcased solid revenue but faced rising R&D costs and leadership changes.
The company's financial stability is supported by cash reserves and expected milestone payments.
Opportunities lie in pipeline advancements, upcoming data releases, and strategic investor communication.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., April  30, 2020  (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on April 30, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 21,000 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).

Spero Therapeutics  Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Spero brings significant commercial leadership and business development experience to its Board of Directors with appointment of pharmaceutical veteran, Scott Jackson Spero brings significant commercial leadership and business development experience to its Board of Directors with appointment of pharmaceutical veteran, Scott Jackson

Spero Announces Appointment of Scott Jackson to its Board of Directors

CAMBRIDGE, Mass., March  31, 2020  (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on March 31, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 31,500 shares of its common stock to five new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule  5635(c)(4)

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -21.10% and 2.46%, respectively, for the quarter ended December 2019.

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass., March  11, 2020  (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for oral SPR720 for the treatment of nontuberculous mycobacterial (NTM) infection.

Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection

CAMBRIDGE, Mass., March  05, 2020  (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the closing of its previously announced rights offering (the “Rights Offering”).  At the closing, Spero sold and issued an aggregate of 1,046,249 shares of its common stock (the “Common Stock”) and an aggregate of 2,287 shares of its Series C convertible preferred stock (“Series C Preferred Stock”) pursuant to the exercise of subscription rights and oversubscription rights in the Rights Offering by existing holders of its Common Stock, Series A convertible preferred stock and Series B convertible preferred stock.  Certain affiliates of BVF Partners L.P., a Spero stockholder, were the sole purchasers of the shares of Series C Preferred Stock sold in the Rights Offering pursuant to the exercise of their subscription and oversubscription rights.  Spero raised aggregate gross proceeds of approximately $30.0 million in the Rights Offering.

Spero Therapeutics Announces Closing of Rights Offering

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Earnings Preview: Spero Therapeutics, Inc. (SPRO) Q4 Earnings Expected to Decline

CAMBRIDGE, Mass., Feb.  28, 2020  (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on February 28, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 24,500 shares of its common stock to two new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).

Spero Therapeutics Announces  Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb.  11, 2020  (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today commenced its previously announced rights offering to raise gross proceeds of $30.0 million (the “Rights Offering”). Under the terms of the Rights Offering, holders of record of Spero’s common stock (“Common Stock”), Series A convertible preferred stock (“Series A Preferred”) and Series B convertible preferred stock (“Series B Preferred”) as of 5:00 p.m., New York time, on February 10, 2020 (the “Record Date”) will receive non-transferable subscription rights entitling them to purchase up to an aggregate of 3,333,333 shares of Common Stock at a subscription price equal to $9.00 per share in proportion to their respective pro rata ownership of Common Stock outstanding (assuming the conversion of all outstanding Series A Preferred and Series B Preferred into shares of Common Stock), or, under certain circumstances, shares of non-voting Series C convertible preferred stock (“Series C Preferred”) in lieu of Common Stock (collectively, the “Offered Shares”), as more fully described in the prospectus supplement, dated February 11, 2020, relating to the Rights Offering. The subscription rights may be exercised any time during the subscription period of February 11, 2020 through 5:00 p.m., New York time, on March 2, 2020.

Spero Therapeutics Announces Commencement of Rights Offering

CAMBRIDGE, Mass., Feb.  05, 2020  (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first contract option for additional committed funding pursuant to its existing contract with Spero.  Specifically, the option exercise provides Spero with $15.9 million in reimbursement for the further development of tebipenem HBr.  Spero’s lead product candidate, tebipenem HBr, is an oral carbapenem currently being evaluated in a pivotal Phase 3 clinical trial for the treatment of complicated urinary tract infections (cUTI), with top-line data expected in the third quarter of 2020. 

Spero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr Development

CAMBRIDGE, Mass., Jan.  31, 2020  (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on January 31, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 6,000 shares of its common stock to two new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).

Spero Therapeutics  Announces  Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$30 Million fully backstopped rights offering will be available to all stockholders of record on February 10, 2020 $30 Million fully backstopped rights offering will be available to all stockholders of record on February 10, 2020

Spero Therapeutics Announces Proposed Rights Offering

Spero (SPRO) reports preliminary findings from a phase I first-in-human study on SPR720, presently being evaluated for the treatment of nontuberculous mycobacterial pulmonary disease.

Spero Posts Preliminary Data on SPR720 for Pulmonary Disease

First indication of human safety and PK profiles for SPR720 supports advancement of program to a Phase 2a proof-of-concept clinical trial in patients planned to initiate in the second half of 2020 First indication of human safety and PK profiles for SPR720 supports advancement of program to a Phase 2a proof-of-concept clinical trial in patients planned to initiate in the second half of 2020

Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease

CAMBRIDGE, Mass., Nov.  29, 2019  (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that on November 29, 2019 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 54,000 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).

Spero Therapeutics -  Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Infectiously Challenging - Spero's Exciting Progress

CAMBRIDGE, Mass., Sept.  30, 2019  (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that on September 30, 2019 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 20,000 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).

Spero Therapeutics (SPRO) Announces Inducement  Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept.  26, 2019  (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that it will present four posters at the Infectious Disease Society of America (IDSA) IDWeek™ 2019 taking place October 2 - 6, 2019 in Washington, DC.  Presentations include one poster on the pharmacokinetics-pharmacodynamics of SPR994, Spero’s oral carbapenem antibiotic product candidate currently in a Pivotal Phase 3 clinical trial for the treatment of complicated urinary tract infections (cUTI), and three posters on cUTI epidemiology and antimicrobial susceptibility.

Spero Therapeutics Announces Presentations at IDWeek 2019

Shares of Spero Therapeutics, Inc. increased about 6% after the company announced that the FDA granted Fast Track designation to SPR994

Spero Gets Fast Track Designation for SPR994, Shares Improve

As of late, it has definitely been a great time to be an investor in Spero Therapeutics.

News for Spero Therapeutics Stock (SPRO)